Modalis Finalist in XPRIZE Healthspan FSHD Prize, Wins Funds
Modalis Therapeutics Corporation, a pioneering company developing innovative products for the treatment of rare genetic diseases utilizing its proprietary CRISPR-GNDM® epigenome editing technology, announced its recognition...